Therapies that boost the anti-tumor responses of cytotoxic T lymphocytes (CTLs) have shown
promise; however, clinical responses to the immunotherapeutic agents currently available …

Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain
metastasis; however, its efficacy in preventing disease progression and the associated toxicity …

Background The role of tumor-associated macrophages (TAMs) in determining the outcome
between the antitumor effects of the adaptive immune system and the tumor’s anti-immunity …

… Garrido-Martin. Material preparation, data collection, and analysis were performed by Suranga
Dharmasiri, Eva M. Garrido-Martin, and Richard J. Harris. The manuscript was written by …

Objective— Hereditary hemorrhagic telangiectasia is a genetic disorder characterized by
visceral and mucocutaneous arteriovenous malformations (AVMs). Clinically indistinguishable …

Stratification of patients for targeted and immune-based therapies requires extensive genomic
profiling that enables sensitive detection of clinically relevant variants and interrogation of …

Aims Activin receptor-like kinase (ALK)1 is a transforming growth factor (TGF)-β type I
membrane receptor restricted almost entirely to endothelial cells (ECs) and involved in vascular …

Recurrent epistaxis is the most frequent clinical manifestation of hereditary haemorrhagic
telangiectasia (HHT). Its treatment is difficult. Our objective was to assess the use of tranexamic …

Background Tumor mutational burden (TMB) is a recently proposed predictive biomarker for
immunotherapy in solid tumors, including non-small cell lung cancer (NSCLC). Available …

Hereditary hemorrhagic telangiectasia (HHT) or Osler–Weber–Rendu syndrome is an autosomal
dominant vascular disorder characterized by telangiectases and internal arteriovenous …